RENO, Nev., July 7, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc. (Pink Sheets:MTNU) Director of Research and Development, Dr. A.W. Martin, announced today that preliminary studies of the new systemic oral enzyme -- Heartzyme(tm) -- are quite encouraging.
In a small group study of patients, the C-reactive protein levels, which indicate the presence of inflammation, were tested. Before beginning Heartzyme(tm) these patients had increased levels of C-reactive protein. Over an 8-week period, the C-reactive protein levels were reduced to normal levels.
Recent studies have linked inflammation to a wide variety of diseases including diabetes, cardiovascular disease and some cancers. "For years researchers were convinced that oxidative damage was the sole culprit in many of these killers, now we know that chronic inflammation caused by smoking, excessive cholesterol and lingering infections can be equally as dangerous," states Dr. Martin.
"We at Martin Nutraceuticals are convinced that our enzyme formulas combined with our powerful anti-oxidant blend can reduce free radicals and low grade inflammation in the body thereby reducing the risk of North America's major causes of death."
"Medicinal anti-inflammatories like Vioxx, Celebrex and other cox-2 inhibitors are not the answer, due to their high incidence of serious side effects," concludes Dr. Martin, "whereas our products are 100% natural with no side effects."
Forward-Looking Statements
This release includes forward-looking statements and projections, made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release, including, without limitation, the ability to implement and achieve our objectives in the long-range plan; actions by the credit rating agencies; the successful close of our financing transactions; our ability to divest of certain assets; inability to realize anticipated synergies and cost savings associated with restructurings and divestitures on a timely basis; the uncertainties associated with governmental regulation; the uncertainties associated with the outcome of governmental investigations; the outcome of pending litigation including shareholder derivative and class actions; difficulty in integration of the operations of previously acquired companies, and competition. While the company makes these statements and projections in good faith, neither the company nor its management can guarantee that anticipated future results will be achieved. The company assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the company, whether as a result of new information, future events, or otherwise.